Fulcrum Therapeutics price target raised to $16 from $12.50 at Piper Sandler

Piper Sandler raised the firm’s price target on Fulcrum Therapeutics (FULC) to $16 from $12.50 and keeps an Overweight rating on the shares. The firm notes Fulcrum will report 20mg pociredir data at ASH in December. Fulcrum disclosed that baseline HbF in the 12 patients enrolled was 7.1% mean. Piper is confident that 20mg pociredir will outperform the 12mg cohort across performance measures.